Home › Funds › RA CAPITAL MANAGEMENT, L.P. › CCCC
RA CAPITAL MANAGEMENT, L.P. position in CCCC
C4 THERAPEUTICS INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 8,000,000 shares of CCCC (C4 THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$37.4M, representing 0.32% of its reported portfolio and ranking #46 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed CCCC holdings in 8 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s CCCC position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in CCCC in Q4 2023 at 4,878,000 shares (US$27.6M). The position peaked in Q1 2024 at 4,878,000 shares, worth US$39.9M. Across 8 filings, RA CAPITAL MANAGEMENT, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 8,000,000 shares valued at US$37.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 4.88M | $27.56M | New |
| Q1 2024 | 4.88M | $39.85M | Hold |
| Q2 2024 | 4.88M | $22.54M | Hold |
| Q3 2024 | 4.88M | $27.80M | Hold |
| Q4 2024 | 4.88M | $17.56M | Hold |
| Q4 2025 | 8.00M | $15.28M | New |
| Q1 2026 | 8.00M | $21.04M | Hold |
| Q2 2026 | 8.00M | $37.36M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in CCCC — the largest reported positions include Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M), Soleus Capital Management, L.P. (US$15.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $33.49M · Q2 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.03M sh · $14.16M · Q2 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- Patient Square Capital LP 1.61M sh · $7.51M · Q2 2026
- HighVista Strategies LLC 1.35M sh · $6.30M · Q2 2026
- Velan Capital Investment Management LP 570.00K sh · $2.66M · Q2 2026
- Squadron Capital Management LLC 400.00K sh · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held CCCC?
RA CAPITAL MANAGEMENT, L.P. has disclosed CCCC holdings in 8 of the last 11 reported quarters, going back to Q4 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in CCCC?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 8.00M shares of CCCC (C4 THERAPEUTICS INC), valued at $37.36M, representing 0.32% of its reported portfolio and ranking #46.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling CCCC?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in CCCC. The position peaked in Q1 2024 at 4.88M shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, Soleus Capital Management, L.P., among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.